

1. Record Nr.	UNINA9910488702303321
Titolo	Cannabinoids and pain // Samer N. Narouze, editor
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2021] ©2021
ISBN	9783030691868 3-030-69186-1
Descrizione fisica	1 online resource (xix, 339 pages) : illustrations (black and white)
Disciplina	615.7827
Soggetti	Cannabinoids - Therapeutic use Pain - Chemotherapy Cànnabis Ús terapèutic Llibres electrònics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Part I: Introduction to Cannabis -- 1: History of Cannabis -- 2: Cannabis Regulations -- Introduction -- Federal Regulations -- State Cannabis Laws -- Research Expansion -- Conclusion -- 3: The Demand for Medical Cannabis Education -- 4: Pain Physicians and Medical Cannabis: Attitudes, Believes, Preparedness and Knowledge -- Introduction -- Development and Description of the Applied Questionnaire -- Statistical Analysis -- Results -- Discussion -- Summary -- Medical Cannabis Questionnaire -- 5: Cannabis Terminology -- Introduction -- General Aspects of the Cannabis Plant -- Differences Between C. sativa and C. indica -- Cannabis Versus Hemp -- The Endocannabinoid System (ECS) -- Key Terminology -- Cannabis Products and Accessories -- Conclusion -- Part II: Cannabinoids Pharmacology -- 6: The Endocannabinoid System -- Introduction -- Brief History of Cannabis and Hemp -- Components of the Endocannabinoid System (ECS) -- eCBs and Their Signal Transduction Pathways -- Complexity of the Endogenous Cannabinoid System -- CB1 and CB2 Receptor -- Other Receptors -- Transporters -- Enzymes -- Physiological Actions of ECS -- 7: Cannabinoid Receptor

1 (CB1) -- CB1 Receptors -- CB1 Receptor Physiology, Pathology, and Pharmacology -- CB1 Signaling -- CB1 Receptor Distribution -- Neocortex -- Hippocampus -- Hypothalamic -- Midbrain Periaqueductal Gray -- Brain Stem Rostral Ventromedial Medulla -- Tolerance -- CB1 Receptor Ligands -- References -- 8: Cannabinoid Receptor 2 (CB2) -- Cannabinoid 2 Receptor -- CB2 Receptor Physiology and Pharmacology -- CB2 Receptor Distribution -- CB2 Signaling -- CB2 Chronic Pain Models -- Tolerance -- CB2 Receptor Ligands.

9: Endocannabinoids: Anandamide and 2-Arachidonoylglycerol (2-AG) -- Introduction -- Biosynthesis and Breakdown Pathways --

Anandamide -- 2-AG -- Endocannabinoids' Mechanism of Action -- Anandamide -- 2-AG -- Plasticity of Endocannabinoid Signaling --

Endocannabinoids in Pain -- Peripheral Mechanisms -- Spinal Mechanisms -- Supraspinal Mechanisms -- Conclusion -- 10:

Phytocannabinoids: Tetrahydrocannabinol (THC) -- Phytocannabinoids -- Introduction -- 9-Tetrahydrocannabinol (THC) -- Mechanism

of Action of THC -- Applied Pharmacology and Pharmacokinetics -- Absorption -- Smoking -- Oral -- Oro-mucosal and Intranasal --

Rectal -- Transcutaneous -- Distribution -- Metabolism

and Elimination -- Conclusion -- 11: Phytocannabinoids: Cannabidiol (CBD) -- Phytocannabinoids -- Cannabidiol and Its Various Clinical

Effects -- Pharmacodynamics of Cannabidiol -- Applied Pharmacology and Pharmacokinetics -- Smoking -- Oral -- Transcutaneous --

Volume of Distribution -- Metabolism -- Elimination -- Safety Profile and Side Effects -- Cannabidiol Interaction with Tetrahydrocannabinol

-- Conclusion -- 12: Other Phytocannabinoids -- Introduction -- Synthesis of Phytocannabinoids -- Cannabinoids

and the Endocannabinoid System (ECS) -- Minor Cannabinoids --

Cannabinol (CBN) -- Cannabigerol (CBG) -- Cannabichromene (CBC) --

Tetrahydrocannabivarin (THCV) -- Conclusion -- 13: Cannabis Drug

Interactions -- Introduction -- Routes of Administration --

Cannabinoid Drug Interactions -- Specific Drug Interactions -- Over-

the-Counter (OTC) Analgesics -- Neuropathic Agents -- Opiates --

Antiepileptics -- Psychotropics -- Anticoagulants and Antiplatelets:

"Blood Thinners" -- Warfarin -- Direct Oral Anticoagulants --

Clopidogrel -- Heparin/Fondaparinux -- References -- Part III:

Pharmaceutical Cannabinoids.

14: Dronabinol (Marinol®) -- Introduction -- Mechanism of Action --

Pharmacokinetics -- Therapeutic Use -- Safety, Toxicity, and Adverse

Effects -- 15: Nabilone (Cesamet) -- Introduction -- Clinical Trials --

Pharmacology and Pharmacokinetics -- Dosage and Administration --

Monitoring, Adverse Events, Drug Interactions, and Abuse Potential --

Adverse Effects -- Drug Interactions -- Abuse Potential -- 16:

Cannabidiol (Epidiolex) -- Introduction -- Clinical Trials --

Pharmacology and Pharmacokinetics -- Dosage and Administration --

Monitoring, Adverse Events, and Drug Interactions -- Adverse Effects

-- Abuse Potential -- 17: Nabiximols (Sativex®) -- Introduction --

Nabiximols Production -- Nabiximols Approval and Indications --

Nabiximols Contraindication -- Nabiximols Evidence -- Nabiximols

for MS-Related Spasticity -- Nabiximols for MS-Related Neuropathic

Pain -- Nabiximols for Cancer-Related Pain -- Nabiximols for Chronic

Pain -- Nabiximols Tolerability -- Nabiximols Dosage

and Administration -- Administration -- Dosing -- Storage, Stability,

and Dosage Form -- Storage and Stability -- Dosage Form -- Summary

-- Part IV: Medical Cannabis -- 18: Cannabis Strains to Chemovars --

Introduction -- Cannabis sativa L. -- Cannabis Cultivation

and Trichomes -- Importance of Trichomes -- Cannabis Constituents

-- Cannabinoids -- Terpenoids -- Other Cannabis Compounds --
Entourage Effect of Cannabis Constituents -- Cannabis Classification:
Strains Versus Chemovars -- Strains -- Chemovar -- Practical
Chemovar Selection for Clinicians -- Summary -- 19: The Model
of a Medical Cannabis Clinic -- Introduction -- Description of a Medical
Cannabis Clinic -- Referral and Screening -- Initial Visit -- Follow-Up
and Monitoring -- Patient Education and Physician Communication.
Protocols and Procedure Guidelines -- Continuing Medical Education --
Research Development -- Conclusion -- References -- 20: Barriers
for the Prescription of Cannabinoid-Based Medicines -- Introduction --
Barriers for Cannabinoid Prescription -- Social Stigma for the Use
of Cannabis -- Myths Versus Realities of Medical Cannabis Use --
Research Gaps and Limitations to Justify Medical Cannabis Use -- Lack
of Knowledge Regarding Cannabis Regulatory Frameworks -- Limited
Medical Cannabis Education -- Development of Medical Cannabis
Education Programs with High Scientific Content -- Conclusion -- 21:
Practical Recommendations for the Use of Medical Cannabis --
Introduction -- Cannabinoid-Based Medicines: What Is Currently
Available? -- Prescription of Pharmaceutical Cannabinoids -- Natural
Cannabis -- Inhalation -- Practical Recommendations [11, 12] -- Oral
Administration -- Practical Recommendations [11, 12] -- Therapeutic
Properties of Cannabinoids: THC Versus CBD -- Practical
Recommendations for the Prescription of Cannabinoid-Based Medicines
-- Clinical Evidence to Support Cannabinoid Use in Specific Medical
Conditions -- Is the Patient a Candidate for Cannabinoid Therapy?
A Systematic Approach -- Conclusion -- 22: Cannabinoid-Based
Medicines: Dosing, Titration & -- Monitoring -- Introduction --
Methods of Administration -- Inhalation: Smoking and Vaporizing --
Oral -- Oromucosal -- Topical -- Dosing -- Concentration and Potency
-- Cannabis Flower Dosing -- Cannabis Oil Dosing -- Achieving
Optimal Therapeutic Dose and Cannabis Rotation -- Cannabis
Chemovar Rotation and Reduction -- Monitoring -- Summary -- 23:
Cannabinoid-Based Medicines: Patient Safety Considerations --
Introduction -- Practical Considerations for Cannabis Use --
Considerations -- Immunocompromised Patients.
Calcineurin Inhibitors, Protein Disulfide Isomerase (PD1) Inhibitors,
and Biologics -- Chronic Kidney Disease -- Older Adults and Patients
with Concurrent Medical Conditions -- Polypharmacy and Drug
Interactions [10] -- Precautions -- Concurrent Active Mood or Anxiety
Disorder -- Patients with Risk Factors for Cardiovascular Disease (CVD)
-- Tobacco Use -- E-Cigarette Use -- Severe Liver Dysfunction or
Disease -- Medications Associated with Sedation or Cognitive
Impairment -- Driving and Safety Sensitive Occupations -- Relative
Contraindications -- Individuals Under the Age of 25 -- Cannabis Use
Disorder (CUD) -- Substance Use Disorder (SUD) and Consideration
for Harm Reduction -- Contraindications -- Cardiovascular Disease --
Respiratory Disease -- Psychosis and Bipolar Disorders -- Pregnancy
and Breastfeeding -- Summary -- Part V: Cannabinoids and Pain -- 24:
Cannabinoids and Pain: Mechanisms of Action -- Introduction --
Endocannabinoids' Mechanism of Action -- Anandamide (AEA) -- 2-
Arachidonoylglycerol (2-AG) -- Endocannabinoids and Pain Modulation
-- Peripheral Mechanisms -- Spinal Mechanisms -- Supraspinal
Mechanisms -- Anandamide and 2-AG Synergistic Effect --
Endocannabinoid Receptors -- CB1 Receptors -- Central CB1 Receptors
-- Peripheral CB1 Receptors -- Central CB2 Receptors -- Peripheral
CB2 Receptors -- Other Putative Endocannabinoid Receptors: TRPV1
and GPR55 -- TRPV1 -- GPR55 -- Phytocannabinoids (THC and CBD)
-- THC -- CBD -- Mechanisms of Action in Pain Modulation -- THC --

CBD -- References -- 25: Cannabinoids and Pain: Clinical Evidence -- Introduction -- Chronic Non-cancer Pain -- Chronic Neuropathic Pain -- Fibromyalgia -- Rheumatoid Arthritis -- Cancer Pain -- Acute Nociceptive Pain -- Summary -- 26: Cannabinoids and Cancer Pain -- Introduction -- Relevant Mechanisms of Cancer Pain. Current Understanding of Clinical Studies.

Sommario/riassunto This book presents a well-balanced view of the potential medical use of cannabinoids in pain. It comprehensively covers the current challenges with medical cannabis utilization and provides recommendations for research and future directions.

2. **Record Nr.** UNINA9910817802903321
- Autore** Foster Robert John <1957->
- Titolo** Materializing the nation : commodities, consumption, and media in Papua New Guinea // Robert J. Foster
- Pubbl/distr/stampa** Bloomington ; ; Indianapolis, Indiana : , : Indiana University Press, , [2002]
©2002
- ISBN** 0-253-21549-8
0-253-01361-5
- Descrizione fisica** 1 online resource (216 p.)
- Disciplina** 305.8/009953
- Soggetti** Anthropology - Papua New Guinea
Ethnopsychology - Papua New Guinea
Nationalism - Papua New Guinea
Consumption (Economics) - Papua New Guinea
Materialism - Social aspects - Papua New Guinea
- Lingua di pubblicazione** Inglese
- Formato** Materiale a stampa
- Livello bibliografico** Monografia
- Note generali** Description based upon print version of record.
- Nota di bibliografia** Includes bibliographical references (pages 183-194) and index.
- Nota di contenuto** Introduction : everyday nation making: the case of Papua New Guinea -- State-sponsored nation making. Take care of public telephones : moral education and nation-state formation. Your money, our money, the government's money : finance and fetishism in Melanesia --

Commercial nation making. Print advertisements and nation making. Commercial mass media : notes on agency, bodies, and commodity consumption. The commercial construction of "new" nations -- Nation making in this era of globalization. News of the world : Millenarian Christianity and the Olympic Torch Relay. Globalization : a soft drink perspective.

Sommario/riassunto

"Foster shows us how seemingly banal activities like making a phone call, chewing betel nut, watching a Coke commercial may give important insights into the ways in which the nation is constructed, materialized or contested."-Orvar Lofgren, author of On Holiday: A History of Vacationing Why, in the current era of globalization, does nationality remain an important dimension of personal and collective identities? In Materializing the Nation, Robert J. Foster argues that the contested process of nation making in Papua New Guinea unfolds not only through organized politics but also thr
